Correlation between serum homocysteine concentration and severity of mitral valve disease in dogs

Objective To measure serum homocysteine concentrations in dogs with myxomatous mitral valve disease (MMVD) and identify any association between this variable and stage of MMVD. Animals 53 client-owned dogs with MMVD and 10 healthy control Beagles. Procedures Dogs with MMVD were allocated to 3 groups in accordance with the staging system for chronic valvular heart disease in dogs and cats of the American College of Veterinary Internal Medicine. Blood samples were collected from all dogs, and serum homocysteine and cardiac troponin I concentrations were measured by enzyme immunoassay and chemiluminescence immunoassay, respectively. Analyte values were tested for associations with each other and with stage of MMVD. Results A significant correlation was identified between serum homocysteine concentration and stage of MMVD. Mean ± SD concentrations were 6.72 ± 1.65 mmol/L for control dogs, 13.37 ± 4.16 mmol/L for dogs with stage B MMVD, 18.86 ± 6.73 mmol/L for dogs with stage C disease, and 28.26 ± 4.48 mmol/L for dogs with stage D disease. In addition, serum homocysteine concentration was correlated with serum cardiac troponin I (r = 0.34) and creatinine (r = 0.46) concentrations, systolic blood pressure (r = 0.57), and left atrium-to-aortic root ratio (r = 0.28), all of which were positively correlated with stage of MMVD. Conclusions and Clinical Relevance Serum homocysteine concentrations of dogs with MMVD were significantly higher than those of control dogs, and significant correlations were identified between these values and several risk factors for heart failure. Measurement of serum homocysteine concentration may be useful in the prediction of severity of disease in dogs with MMVD.